Welcome to the home of Neuralgene...

home-imgNeuralgene is a biotechnology company with its’ flagship gene therapy platform a neurotropic AAV gene therapy designed to treat the neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS). Neuralgene has partnered with Helica Labs to begin production of several AAV gene therapies in its' R&D pipeline for the treatment of other neural diseases such as Parkinson’s, Adronoleukodystrophy and ALS. Neuralgene has initiated initial human testing in it’s gene therapies for ALS and ALD.

Latest News & Posts

Neuralgene announces partnership with Precision StemCell of Bogota, Colombia

Neuralgene announces partnership with Precision StemCell of Bogota, Colombia to…

split

Neuralgene announces a larger study in the ALS mouse model to evaluate efficacy of PRCN-829

Neuralgene initial animal testing demonstrates safety of their gene therapy…

split

To begin testing with genetically engineered stem cell therapy

Neuralgene is partnering with Precision StemCell in Bogota, Colombia to begin testing with genetically engineered…